Risperdal "approvable" for autism
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Johnson & Johnson's antipsychotic Risperdal (risperidone) is "approvable" for treatment of autism in adolescents and children. The sNDA, submitted Dec. 19, 2003, received a priority review. Risperdal could be the first product approved for autism...
Johnson & Johnson's antipsychotic Risperdal (risperidone) is "approvable" for treatment of autism in adolescents and children. The sNDA, submitted Dec. 19, 2003, received a priority review. Risperdal could be the first product approved for autism.... |